Department of Clinical Diabetes and Epidemiology, Baker Heart and Diabetes Institute, Melbourne, Australia; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.
Department of Clinical Diabetes and Epidemiology, Baker Heart and Diabetes Institute, Melbourne, Australia; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.
Am J Kidney Dis. 2018 Nov;72(5):653-661. doi: 10.1053/j.ajkd.2018.02.364. Epub 2018 May 18.
Reduced glomerular filtration rate (GFR) in the absence of albuminuria is a common manifestation of chronic kidney disease (CKD) in diabetes. However, the frequency with which it progresses to end-stage kidney disease (ESKD) is unknown.
Multicenter prospective cohort study.
SETTING & PARTICIPANTS: We included 1,908 participants with diabetes and reduced GFR enrolled in the Chronic Renal Insufficiency Cohort (CRIC) Study in the United States.
Urinary albumin and protein excretion.
Incident ESKD, CKD progression (ESKD or ≥50% reduction in estimated GFR [eGFR] from baseline), and annual rate of decline in kidney function.
ESKD was ascertained by self-report and by linkage to the US Renal Data System. We used Cox proportional hazards modeling to estimate the association of albuminuria and proteinuria with incident ESKD or CKD progression and linear mixed-effects models to assess differences in eGFR slopes among those with and without albuminuria.
Mean eGFR at baseline was 41.2mL/min/1.73m. Normal or mildly increased 24-hour urinary albumin excretion (<30mg/d) at baseline was present in 28% of participants, but in only 5% of those progressing to ESKD. For those with baseline normal or mildly increased albuminuria, moderately increased albuminuria (albumin excretion, 30-299mg/d), and 2 levels of severely increased albuminuria (albumin excretion, 300-999 and ≥1,000mg/d): crude rates of ESKD were 7.4, 34.8, 78.7, and 178.7 per 1,000 person-years, respectively; CKD progression rates were 17.0, 61.4, 130.5, and 295.1 per 1,000 person-years, respectively; and annual rates of eGFR decline were -0.17, -1.35, -2.74, and -4.69mL/min/1.73m, respectively.
We were unable to compare the results with healthy controls.
In people with diabetes with reduced eGFRs, the absence of albuminuria or proteinuria is common and carries a much lower risk for ESKD, CKD progression, or rapid decline in eGFR compared with those with albuminuria or proteinuria. The rate of eGFR decline in normoalbuminuric CKD was similar to that reported for the general diabetic population.
在没有蛋白尿的情况下肾小球滤过率(GFR)降低是糖尿病慢性肾脏病(CKD)的常见表现。然而,它进展为终末期肾病(ESKD)的频率尚不清楚。
多中心前瞻性队列研究。
我们纳入了在美国慢性肾功能不全队列(CRIC)研究中患有糖尿病和 GFR 降低的 1908 名参与者。
尿白蛋白和蛋白排泄。
新发 ESKD、CKD 进展(ESKD 或 eGFR 从基线下降≥50%)以及肾功能每年下降速度。
ESKD 通过自我报告和与美国肾脏数据系统的链接来确定。我们使用 Cox 比例风险模型估计白蛋白尿和蛋白尿与新发 ESKD 或 CKD 进展的相关性,并使用线性混合效应模型评估有和无白蛋白尿患者之间 eGFR 斜率的差异。
基线时的平均 eGFR 为 41.2mL/min/1.73m。基线时正常或轻度增加的 24 小时尿白蛋白排泄(<30mg/d)在 28%的参与者中存在,但在进展为 ESKD 的患者中仅占 5%。对于基线时正常或轻度增加白蛋白尿的患者,中度增加白蛋白尿(白蛋白排泄,30-299mg/d)和 2 个严重增加白蛋白尿水平(白蛋白排泄,300-999 和≥1000mg/d):ESKD 的粗发生率分别为每 1000 人年 7.4、34.8、78.7 和 178.7;CKD 进展率分别为每 1000 人年 17.0、61.4、130.5 和 295.1;eGFR 每年下降速度分别为-0.17、-1.35、-2.74 和-4.69mL/min/1.73m。
我们无法将结果与健康对照组进行比较。
在患有糖尿病和降低的 eGFR 的患者中,无白蛋白尿或蛋白尿很常见,与有白蛋白尿或蛋白尿的患者相比,ESKD、CKD 进展或 eGFR 快速下降的风险要低得多。在正常白蛋白尿性 CKD 中,eGFR 的下降速度与一般糖尿病患者报告的速度相似。